BDBM315618 6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinazolin-4-yl)phenyl]- hydroxymethyl}-2- methyl-2H-pyridazin-3- one (Ena 2)1H NMR (500 MHz, DMSO-d6) ppm = 9.12 (s, 1H), 7.93 (d, J = 7.7, 1H), 7.68 (d, J = 9.5, 1H), 7.61- 7.52 (m, 2H), 7.48 (d, J = 9.6, 1H), 7.21 (d, J = 2.4, 1H), 6.93 (d, J = 9.6, 1H), 6.60 (d, J = 4.8, 1H), 5.89 (d, J = 4.8, 1H), 3.80-3.75 (m, 4H), 3.59 (s, 3H), 3.48-3.43 (m, 4H)::US10172859, Example 44::US10172859, Example 45::US10172859, Example 59::US11065253, Example 59::US9732094, Example 59

SMILES Cn1nc(ccc1=O)C(O)c1cc(c(F)cc1Cl)-c1ncnc2cc(ccc12)N1CCOCC1

InChI Key InChIKey=TYZMCDRHMQABIJ-UHFFFAOYSA-N

Data  6 KI  9 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 315618   

TargetDNA-dependent protein kinase catalytic subunit(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataIC50: 18.5nMAssay Description:The kinase assay was carried out in streptavidin-coated 348-well microtitre flashplates. To this end, 1.5 μg of DNA-PK/protein complex and 100 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataIC50: 3nMAssay Description:The kinase assay was carried out in streptavidin-coated 348-well microtitre flashplates. To this end, 1.5 μg of DNA-PK/protein complex and 100 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataIC50: 3nMAssay Description:The kinase assay was carried out in streptavidin-coated 348-well microtitre flashplates. To this end, 1.5 μg of DNA-PK/protein complex and 100 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataIC50: 19nMAssay Description:The kinase assay was carried out in streptavidin-coated 348-well microtitre flashplates. To this end, 1.5 ug of DNA-PK/protein complex and 100 ng of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2019
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataIC50: 3nMAssay Description:The kinase assay was carried out in streptavidin-coated 348-well microtitre flashplates. To this end, 1.5 ug of DNA-PK/protein complex and 100 ng of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2019
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataIC50: 3nMAssay Description:The kinase assay was carried out in streptavidin-coated 348-well microtitre flashplates. To this end, 1.5 ug of DNA-PK/protein complex and 100 ng of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2019
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataIC50: 18.5nMAssay Description:The kinase assay was carried out in streptavidin-coated 348-well microtitre flashplates. To this end, 1.5 μg of DNA-PK/protein complex and 100 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataIC50: 3nMAssay Description:The kinase assay was carried out in streptavidin-coated 348-well microtitre flashplates. To this end, 1.5 μg of DNA-PK/protein complex and 100 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataIC50: 3nMAssay Description:The kinase assay was carried out in streptavidin-coated 348-well microtitre flashplates. To this end, 1.5 μg of DNA-PK/protein complex and 100 n...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2021
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataKi:  2.00E+4nMAssay Description:Method for the detection and characterisation of test substances which interfere with the Kv11.1 (hERG) channel: Kv11.1 (hERG, human ether a-go-go re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataKi:  2.00E+4nMAssay Description:Method for the detection and characterisation of test substances which interfere with the Kv11.1 (hERG) channel: Kv11.1 (hERG, human ether a-go-go re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataKi:  2.00E+4nMAssay Description:Method for the detection and characterisation of test substances which interfere with the Kv11.1 (hERG) channel: Kv11.1 (hERG, human ether a-go-go re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataKi:  2.00E+4nMAssay Description:The patch-clamp measurement was carried out at room temperature in whole-cell configuration on human embryonic kidney cells (HEK293) which have been ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2019
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataKi:  2.00E+4nMAssay Description:The patch-clamp measurement was carried out at room temperature in whole-cell configuration on human embryonic kidney cells (HEK293) which have been ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2019
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Merck Patent

US Patent
LigandPNGBDBM315618(6-{[2-Chloro-4-fluoro-5- (7-morpholin-4-yl- quinaz...)
Affinity DataKi:  2.00E+4nMAssay Description:The patch-clamp measurement was carried out at room temperature in whole-cell configuration on human embryonic kidney cells (HEK293) which have been ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2019
Entry Details
Go to US Patent